Clinical trials in Pamplona – page 5

761 clinical trials in Pamplona, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Pamplona at a glance

761

clinical trials

Research sites1

Quick filters

761 trials in Pamplona

Open in trial search

Pancreatic carcinoma metastatic

Recruiting

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Gemcitabine
Sponsor:Revolution Medicines Inc.

Contact Research Centre

Asthma

Recruiting

Efficacy and Safety of Depemokimab for Early Intervention in Adults and Adolescents with Type 2 Asthma at Risk of Exacerbations

Registered drug

Efficacy and Safety of Depemokimab for Early Intervention in Adults and Adolescents with Type 2 Asthma at Risk of Exacerbations

Registered drug

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Depemokimab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Plasma cell myeloma

Recruiting

Cevostamab, Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 1‑3 Lines of Therapy

Registered drugNo placebo

Cevostamab, Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 1‑3 Lines of Therapy

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Carfilzomib
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Plasma cell myeloma refractory

Recruiting

Phase 3 Study Comparing JNJ-79635322 with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma after 1‑3 Prior Treatments

InvestigationalNo placebo

Phase 3 Study Comparing JNJ-79635322 with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma after 1‑3 Prior Treatments

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Teclistamab
Sponsor:Janssen Cilag International

Contact Research Centre

Colorectal cancer+2

Recruiting

Study of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors

Registered drugNo placebo

Study of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Revolution Medicines Inc.

Contact Research Centre

Chronic cutaneous lupus erythematosus+2

Recruiting

Phase 3 Study of Enpatoran in Patients with Active Cutaneous Lupus Erythematosus (with or without Systemic Disease)

Investigational

Phase 3 Study of Enpatoran in Patients with Active Cutaneous Lupus Erythematosus (with or without Systemic Disease)

Investigational

Spain

Participants:18–64 years · 65+ years
Sponsor:Merck Healthcare KGaA

Contact Research Centre

Bladder cancer

Recruiting

Study of Enfortumab Vedotin and Pembrolizumab for Bladder Preservation in Patients with Muscle‑Invasive Bladder Cancer

Registered drugNo placebo

Study of Enfortumab Vedotin and Pembrolizumab for Bladder Preservation in Patients with Muscle‑Invasive Bladder Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Enfortumab Vedotin
Sponsor:Astellas Pharma Global Development Inc.

Contact Research Centre

Oesophageal adenocarcinoma

Recruiting

Switch maintenance with paclitaxel, ramucirumab and tislelizumab versus continued chemotherapy with tislelizumab in HER2‑negative, PD‑L1‑positive gastroesophageal cancer

Registered drugNo placebo

Switch maintenance with paclitaxel, ramucirumab and tislelizumab versus continued chemotherapy with tislelizumab in HER2‑negative, PD‑L1‑positive gastroesophageal cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Fondazione GONO G.I.

Contact Research Centre

Gastric cancer+1

Recruiting

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:AZD0901
Sponsor:AstraZeneca AB

Contact Research Centre

Oesophageal adenocarcinoma

Recruiting

Study of denikitug alone or with drug combination in adults with HER2‑negative metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma

Registered drugNo placebo

Study of denikitug alone or with drug combination in adults with HER2‑negative metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Nivolumab
Sponsor:Gilead Sciences Inc.

Contact Research Centre

Lupus nephritis

Recruiting

Safety and early efficacy of TranspoCART19 CAR‑T CD19 therapy in patients with refractory lupus nephritis (Phase I‑IIa)

InvestigationalNo placebo

Safety and early efficacy of TranspoCART19 CAR‑T CD19 therapy in patients with refractory lupus nephritis (Phase I‑IIa)

InvestigationalNo placebo

Spain

Participants:18–64 years
Substances:Transpocart19
Sponsor:Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz

Contact Research Centre

Mantle cell lymphoma

Recruiting

Phase 3 Study of Orelabrutinib with Rituximab and Bendamustine vs. Rituximab and Bendamustine in Treatment‑Naïve Mantle Cell Lymphoma Patients

Registered drug

Phase 3 Study of Orelabrutinib with Rituximab and Bendamustine vs. Rituximab and Bendamustine in Treatment‑Naïve Mantle Cell Lymphoma Patients

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Rituximab

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Pamplona

What the registry says about research in the country

01 Oncology Research

Innovative trials exploring treatments for various cancers, including metastatic colorectal cancer, bladder cancer, and prostate cancer. Studies focus on combination therapies and novel treatment approaches.

Colorectal Cancer Treatment Studies
Prostate Cancer Therapies
Blood Cancer Research

Multiple trials evaluating immunotherapies and targeted treatments for improving patient outcomes.

02 Immunology and Inflammation

Research focused on treating autoimmune conditions and inflammatory disorders, including studies on cutaneous lupus erythematosus and atopic dermatitis.

Lupus Treatment Studies
Dermatological Conditions
Immune System Disorders

Evaluating new therapeutic approaches for chronic inflammatory conditions.

03 Respiratory Medicine

Clinical investigations targeting respiratory conditions, including studies on COPD and respiratory viral infections. Research focuses on improving treatment outcomes.

COPD Management
Respiratory Virus Prevention
Nasal Polyps Treatment

Development of innovative therapies for respiratory diseases and infections.

04 Metabolic Disorders

Studies addressing obesity, diabetes, and related metabolic conditions. Research focuses on weight management and blood sugar control.

Type 2 Diabetes Treatment
Weight Management Therapies
Metabolic Disease Research

Investigating new approaches for metabolic disorder management.

Back to Spain All countries